Related Experiment Videos
New developments in immunotherapy for non-Hodgkin's lymphoma
John P Leonard1, Richard R Furman, Jia Ruan
1Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA. jpleonar@med.cornell.edu
Current Oncology Reports
|August 11, 2005
Summary
Rituximab, a chimeric anti-CD20 monoclonal antibody, has transformed B-cell non-Hodgkin's lymphoma treatment. Research continues to optimize its use, including combinations and radiolabeled versions, for improved patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Hematology
Background:
- Rituximab (chimeric anti-CD20 monoclonal antibody) has significantly impacted B-cell non-Hodgkin's lymphoma (NHL) treatment.
- Its efficacy was first established in relapsed indolent lymphoma, both as a monotherapy and in combination regimens.
Purpose of the Study:
- To review the clinical development and evolving treatment strategies involving rituximab in NHL.
- To explore ongoing research in optimizing rituximab dosing, scheduling, and combination therapies.
Main Methods:
- Review of clinical development and trial data for rituximab in various NHL subtypes.
- Analysis of studies investigating maintenance strategies, combination therapies, and radiolabeled anti-CD20 antibodies.
Main Results:
- Rituximab demonstrates substantial activity in relapsed indolent NHL and improves survival when added to CHOP chemotherapy in diffuse large B-cell lymphoma.
- Radiolabeled anti-CD20 antibodies show promise in relapsed/refractory disease and potentially in initial treatment.
- Benefits are less pronounced in mantle cell lymphoma.
Conclusions:
- Rituximab is a cornerstone therapy for B-cell NHL, with ongoing research focused on maximizing its clinical benefit.
- Further investigation into both unlabeled and radiolabeled immunotherapies is crucial for optimizing treatment strategies.